HHS 允许药房和医生临时配制六种实验性肽类，FDA 科学家提出质疑
STAT+: HHS green lights six peptides, despite concerns from FDA scientists
HHS 发布政策，允许持证药房和医生临时配制六种实验性肽类，包括 BPC-157 和 TB-500，且不担心联邦执法。STAT 的 Margaret Manto 报道称，FDA 职业科学家对此表示反对，认为几乎没有证据表明这些物质安全或有效。
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
I have a cold again. Cure it, science.
HHS opens peptide floodgates, despite concerns from FDA scientists
The Trump administration is giving the peptide craze a regulatory boost. HHS issued a policy allowing licensed pharmacies and physicians to temporarily compound six experimental peptides, including the popular injury-recovery duo BPC-157 and TB-500, without fear of federal enforcement, STAT’s Margaret Manto writes. This comes despite objections from FDA career scientists who say there’s scant evidence the substances are safe or effective.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源：STAT News · statnews.com